ScholarLens Back to search
2017•Prenatal DiagnosisRequires access

Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA

Barbara M. O’Brien, Jacquelyn V. Halliday, Geralyn M. Lambert-Messerlian, Elizabeth E. Eklund, Edward M. Kloza, Glenn E. Palomaki

Open publisher page 7 citations

Abstract

What's already known about this topic? Nuchal translucency measurement in the first trimester is a proven marker to assess risk of common aneuploidies. Prenatal screening using cfDNA performs better than any combined ultrasound and serum marker test. The value of an NT scan in women having screening by cfDNA is questionable. What does this study add? A positive NT ultrasound scan did not add to the cases of aneuploidy that were detected by cfDNA screening.

About this research paper

What this paper is about

What's already known about this topic? Nuchal translucency measurement in the first trimester is a proven marker to assess risk of common aneuploidies. Prenatal screening using cfDNA performs better than any combined ultrasound and serum marker test. The value of an NT scan in women having screening by cfDNA is questionable. What does this study add? A positive NT ultrasound scan did not add to the cases of aneuploidy that were detected by cfDNA screening.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

What's already known about this topic? Nuchal translucency measurement in the first trimester is a proven marker to assess risk of common aneuploidies. Prenatal screening using cfDNA performs better than any combined ultrasound and serum marker test. The value of an NT scan in women having screening by cfDNA is questionable. What does this study add? A positive NT ultrasound scan did not add to the cases of aneuploidy that were detected by cfDNA screening.

Key concepts: Aneuploidy, Nuchal Translucency Measurement, Cell-free fetal DNA, Nuchal translucency, Medicine, Obstetrics, Prenatal screening, Prenatal diagnosis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA — Research Paper | ScholarLens